Empagliflozin
This medication belongs to a group called SGLT2 inhibitors. It is used to treat heart failure. The medication works by helping the kidneys remove excess sugar from the blood through urine. In this trial, it is being studied to see if continuing its use during hospital stays for worsening heart failure is beneficial for patients who were already taking SGLT2 inhibitors before being admitted to the hospital.

SGLT2 inhibitors
This is a class of medications that help control blood sugar levels and can improve heart function. These medications work by preventing the kidneys from reabsorbing sugar back into the blood, instead allowing it to be removed through urine. Patients in this trial were already using these medications before their hospital admission for heart failure symptoms.

Acute Decompensated Heart Failure – A severe condition where the heart suddenly cannot pump blood effectively enough to meet the body’s needs. It occurs when chronic heart failure worsens or develops rapidly, leading to fluid buildup in the lungs and other body tissues. The main symptoms include severe shortness of breath, rapid or irregular heartbeat, and swelling in the legs and ankles. This condition typically causes fatigue and difficulty breathing, especially when lying down. The heart’s reduced pumping ability leads to congestion in various parts of the body, causing fluid retention and decreased organ function.